Evaluation and Survey of Intravenous Vitamin K1 for Treatment of Coagulopathy in Critically Ill Patients

• DOI: 10.1592/phco.21.2.175.34111
• Publication Date: 2004-06-07T09:03:57Z
• Authors: Robert MacLaren; S. Jo‐Anne Wilson; Amanda Campbell; David Anderson; Graeme Rocker
• Keywords: Adult; Male; Canada; Chi-Square Distribution; Data Collection; Vitamin K 1; Disseminated Intravascular Coagulation; Middle Aged; Antifibrinolytic Agents; Statistics, Nonparametric; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Linear Models; Humans; Female; Partial Thromboplastin Time; International Normalized Ratio; Prospective Studies; APACHE; Aged; Retrospective Studies

Study Objectives. To determine patient factors associated with coagulopathy, to assess variables affecting response vitamin K 1 , describe ‐associated adverse reactions, and survey Canadian tertiary care hospitals about practice patterns in their intensive units (ICUs). Design. Retrospective chart audit prospective survey. Setting. Medical‐surgical ICU a 23‐bed complement care, university‐affiliated hospital, 47 hospitals. Patients. Forty‐eight critically ill patients nonconsumptive coagulopathies. Intervention. Intravenous utilization over 4 months. Measurements Main Results. The only independent risk factor for elevated baseline international normalized ratios (INRs) was Acute Physiologic Chronic Health Evaluation (APACHE) II score (r 2 = 0.51, p<0.05). INR values decreased after two doses of 10 mg grouped as whole (2.14 ± 0.96 1.61 0.62, p<0.0001) when were stratified according APACHE scores below 23 (1.83 0.44 1.34 0.18, INRs not significantly reduced or greater (2.44 1.23 1.82 0.66). No response, events observed. Of surveyed, 27 (55%) responded. Twenty‐four (89%) indicated that administered intravenously, no resembling anaphylaxis reported. Conclusion. Administration intravenous reversal coagulopathies, but variable responses may be expected high scores. Randomized, placebo‐controlled studies are necessary confirm the effectiveness .